Our goal in this study was to demonstrate a better outcome and a greater impact on the metabolic syndrome and liver disease progression associated with NAFLD with our nanosystem than with the subcutaneous injection of the GLP-1 analog alone. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.